Myriad Genetics, Inc.

The momentum for this stock is not very good. Myriad Genetics, Inc. has good growth characteristics. Myriad Genetics, Inc. is not very popular among insiders. Myriad Genetics, Inc. is a mediocre stock to choose.
Log in to see more information.
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecul...
MYGN Fundamental Data by TradingView

News

Heinrich Dreismann Sells 10,000 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) Stock
Heinrich Dreismann Sells 10,000 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) Stock

Ticker Report Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) Director Heinrich Dreismann sold 10,000 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price...\n more…

Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?
Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research A month has gone by since the last earnings report for Myriad Genetics (MYGN). Shares have lost about 4.8% in that time frame, underperforming the S&P 500.Will the recent negative trend continue...\n more…

Myriad Genetics to Host Investor Event on October 9, 2024
Myriad Genetics to Host Investor Event on October 9, 2024

Globe Newswire SALT LAKE CITY, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Event at the Westin Grand Central...\n more…

Myriad Genetics, Inc. (NASDAQ:MYGN) Director Colleen F. Reitan Sells 46,012 Shares
Myriad Genetics, Inc. (NASDAQ:MYGN) Director Colleen F. Reitan Sells 46,012 Shares

Ticker Report Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) Director Colleen F. Reitan sold 46,012 shares of the company's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold...\n more…

Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term

Zacks Investment Research It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different...\n more…

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking

Simply Wall St You may think that with a price-to-sales (or "P/S") ratio of 3.2x Myriad Genetics, Inc. ( NASDAQ:MYGN ) is definitely a...\n more…